Roivant Sciences
ROIV · NasdaqPharmaceutical Preparations · Fiscal year ends Mar 31
Roivant Sciences reported revenue of $8M in the fiscal year ended Mar 2026, down 71.6% from the year before. Operating income was −$515M, an operating margin of −6235.7%, and net income was −$300M. Operating cash flow of −$750M less capital expenditure of $8M left free cash flow of −$759M.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | $55M | $32M | $33M | $29M | $8M |
| Research & development | $483M | $454M | $440M | $550M | $682M |
| Selling, general & admin | $775M | $601M | $687M | – | – |
| Operating income | −$1.4B | −$907M | $4.5B | −$1B | −$515M |
| Interest expense | $7M | $28M | $35M | – | – |
| Pre-tax income | −$924M | −$885M | $4.6B | −$682M | −$265M |
| Income tax | $369,000 | $4M | $22M | $48M | $133M |
| Net income | −$845M | −$1B | $4.3B | −$172M | −$300M |
| Diluted EPS | −1.26 | −1.42 | 5.23 | −0.24 | −0.54 |
| Diluted shares | 670M | 713M | 831M | 725M | 694M |
Balance sheet
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | $2.1B | $1.7B | $6.5B | $2.7B | $1.4B |
| Receivables | $4M | $30M | $4M | – | – |
| Inventory | $0 | $3M | $35M | – | – |
| Current assets | $2.1B | $1.8B | $6.7B | $5B | $5.2B |
| Net PP&E | $26M | $39M | $15M | $12M | $12M |
| Total assets | $2.6B | $2.4B | $7.2B | $5.4B | $5.7B |
| Payables | $35M | $38M | $14M | $24M | $18M |
| Deferred revenue | $10M | $12M | $4M | $1M | – |
| Current liabilities | $184M | $272M | $267M | $149M | $281M |
| Short-term debt | $0 | $41M | $12M | – | – |
| Long-term debt | $210M | $376M | $431M | – | – |
| Total liabilities | $524M | $782M | $774M | $250M | $416M |
| Shareholders' equity | $1.7B | $1.2B | $6B | $4.7B | $4.5B |
Cash flow
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating cash flow | −$678M | −$843M | −$765M | −$839M | −$750M |
| Capital expenditure | $17M | $13M | $1M | $5M | $8M |
| Free cash flow | −$695M | −$856M | −$767M | −$844M | −$759M |
| Depreciation & amortisation | $6M | $19M | $22M | $14M | $3M |
| Stock-based compensation | $565M | $218M | $200M | $289M | $346M |
| Share buybacks | – | $0 | $0 | $1.3B | – |
Key ratios
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −43.0% | 3.8% | −11.2% | −71.6% |
| Operating income growth (YoY) | – | – | – | −122.3% | – |
| EPS growth (YoY) | – | – | – | −104.6% | – |
| Operating margin | −2444.8% | −2875.9% | 13746.9% | −3453.3% | −6235.7% |
| Net margin | −1528.9% | −3200.2% | 13294.2% | −592.0% | −3629.2% |
| Return on equityBlank when equity is negative | −51.0% | −87.2% | 72.9% | −3.7% | −6.6% |
| ROCEEBIT ÷ (assets − current liabilities) | −56.3% | −42.8% | 64.7% | −19.0% | −9.5% |
| Free cash flow margin | −1257.4% | −2715.1% | −2343.6% | −2905.2% | −9183.5% |
| Cash conversion (CFO ÷ net income) | 0.80x | 0.84x | −0.18x | 4.88x | 2.50x |
| Receivable days | 26 | 352 | 45 | – | – |
| Interest cover | −192x | −32.4x | 129x | – | – |
| Debt ÷ equity | 0.13x | 0.36x | 0.07x | – | – |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −$1.9B | −$1.3B | −$6.1B | – | – |
| Current ratio | 11.6x | 6.60x | 25.2x | 33.5x | 18.4x |
Recent filings
More in Pharmaceutical Preparations
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.